LB Pharmaceuticals
NASDAQ: LBRXNew York, US · Delaware corporation · 4 known investors
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.
Founders & leadership
ZP
Zachary PrenskyFounder
LS
Lauren StippExecutive
MP
Mark PanoffExecutive
Board
ES
Edmund SullivanBoard director
VG
Vincent GrattanBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$141.4M disclosed across 9 rounds · 2016–2023
▶$110.7MraisedJan 2024 · 6 investors · PharmaceuticalsRule 506(b)
▶$110.7MraisedJan 2024 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rajul JainDirector
- Ran NussbaumDirector
- Zachary PrenskyExecutive Officer, Director
- Robert RuffoloDirector
- Andrew VainoExecutive Officer
- Anna EramoExecutive Officer
- Marc PanoffExecutive Officer
- Rebecca LuseDirector
- Chen YuDirector
- Offering amount
- $110.7M
- Amount sold
- $110.7M
- Sales commissions
- $2.5M
- Finders' fees
- $735K
- Proceeds to insiders
- $1.3M
- Placement agents
- Agile Capital Markets, Maxim Group LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.6MraisedNov 2022 · 71 investors · PharmaceuticalsRule 506(b)
▶$16.6MraisedNov 2022 · 71 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edmund SullivanDirector
- Vincent GrattanDirector
- Piero PoliDirector
- Zachary PrenskyExecutive Officer, Director
- Marc PanoffExecutive Officer
- Robert RuffoloDirector
- Offering amount
- $40M
- Amount sold
- $16.6M
- Minimum investment
- $25K
- Sales commissions
- $1.7M
- Proceeds to insiders
- $437.2K
- Placement agents
- Maxim Group LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$903.4KraisedJul 2022 · 35 investors · PharmaceuticalsRule 506(b)
▶$903.4KraisedJul 2022 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert RuffoloDirector
- Marc PanoffExecutive Officer
- Vincent GrattanDirector
- Edmund SullivanDirector
- Piero PoliDirector
- Zachary PrenskyExecutive Officer, Director
- Amount sold
- $903.4K
- Sales commissions
- $85.9K
- Proceeds to insiders
- $115K
- Placement agents
- Maxim Group LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.6MraisedSep 2020 · 35 investors · PharmaceuticalsRule 506(b)
▶$4.6MraisedSep 2020 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Piero PoliDirector
- Vincent GrattanDirector
- Edmund SullivanDirector
- Marc PanoffExecutive Officer
- Robert RuffoloDirector
- Zachary PrenskyExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $4.6M
- Minimum investment
- $10K
- Sales commissions
- $455.4K
- Proceeds to insiders
- $454K
- Placement agents
- Maxim Group LLC
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$6.3MraisedDec 2018 · 74 investors · PharmaceuticalsRule 506(b)
▶$6.3MraisedDec 2018 · 74 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marc PanoffExecutive Officer
- Andrew VainoExecutive Officer
- Edmund SullivanDirector
- Vincent GrattanDirector
- Zachary PrenskyExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $6.3M
- Minimum investment
- $25K
- Sales commissions
- $670.2K
- Proceeds to insiders
- $550K
- Placement agents
- Maxim Group LLC
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$443.2KraisedAug 2018 · 7 investors · PharmaceuticalsRule 506(b)
▶$443.2KraisedAug 2018 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Zachary PrenskyExecutive Officer, Director
- Andrew VainoExecutive Officer
- Vincent GrattanDirector
- Mark PanoffExecutive Officer
- Edmund SullivanDirector
- Offering amount
- $443.2K
- Amount sold
- $443.2K
- Minimum investment
- $10K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$330KraisedMay 2018 · 11 investors · PharmaceuticalsRule 506(b)
▶$330KraisedMay 2018 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Zachary PrenskyExecutive Officer, Director
- Andrew VainoExecutive Officer
- Vincent GrattanDirector
- Edmund SullivanDirector
- Mark PanoffExecutive Officer
- Offering amount
- $750K
- Amount sold
- $330K
- Minimum investment
- $10K
- Proceeds to insiders
- $30K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$462KraisedApr 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$462KraisedApr 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edmund SullivanDirector
- Lauren StippExecutive Officer
- Mark PanoffExecutive Officer
- Vincent GrattanDirector
- Zachary PrenskyExecutive Officer, Director
- Offering amount
- $462K
- Amount sold
- $462K
- Minimum investment
- $10K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Seeking Alpha9 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St8 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with LB Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does LB Pharmaceuticals do?
- A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.
- Who founded LB Pharmaceuticals?
- LB Pharmaceuticals was founded by Zachary Prensky.
- Who are LB Pharmaceuticals's investors?
- LB Pharmaceuticals's investors include Pontifax Venture Capital, Tarnagulla Ventures, Vida Ventures, TCG Crossover.
- How much funding has LB Pharmaceuticals raised?
- LB Pharmaceuticals has disclosed $141.4M raised across 9 rounds.
- Where is LB Pharmaceuticals headquartered?
- LB Pharmaceuticals is headquartered in New York, US.